This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Similar Posts
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) InitiativeFDA Rationale for Recognition Decision: Isavuconazonium sulfate
FDA Rationale for Recognition Decision: Isavuconazonium sulfateMissouri Analytical Laboratories Inc – 615319 – 10/09/2024
CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedGilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for Injection 100 mg/vial Due to the Presence of a Glass Particle
Foster City, Calif., September 20, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer complaint and confirmed the presence of a glass particle inPushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi – 709156 – 06/16/2025
CGMP/Finished Pharmaceuticals/AdulteratedNew England Home Therapies Inc. Southborough, MA. 483 Issued 01/27/2016
Record Date 01/27/2016
FEI Number 1000120535
Firm Name New England Home Therapies Inc.
Record Type 483
State MA
Establishment Type Producer of Sterile Drug Products